Department of Orthopedics, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China (mainland).
Med Sci Monit. 2023 Sep 12;29:e941003. doi: 10.12659/MSM.941003.
BACKGROUND Thoracolumbar spinal tuberculosis is a severe form of extrapulmonary tuberculosis requiring precise management strategies. Traditionally, patients undergo a 2-4 week course of preoperative quadruple chemotherapy before surgery. However, recent clinical practices have begun exploring the potential of a short-course (1-7 days) intensive preoperative chemotherapy regimen. This study aims to examine and compare the clinical effectiveness of both approaches, offering critical insights into the optimal preoperative chemotherapy duration. MATERIAL AND METHODS In this retrospective analysis, we examined the clinical data from 123 patients with surgically treated thoracolumbar spinal tuberculosis. Patients were categorized into two groups based on the duration of preoperative chemotherapy: the short-course intensive chemotherapy group (n=53, 1-7 days) and the traditional quadruple chemotherapy group (n=70, 2-4 weeks). We gathered and compared the pertinent clinical data from both groups to ascertain differences in clinical efficacy. RESULTS All 123 patients underwent follow-up for a duration averaging 2.8±0.7 years. Five patients experienced postoperative recurrence. Patients reported significant pain alleviation and overall good clinical outcomes. Among patients with neurological dysfunction, neurological symptoms were ameliorated, and the implanted devices were found to be effective. Bony fusion was observed in all the bone grafting regions. CONCLUSIONS For patients suffering from thoracolumbar spinal tuberculosis exhibiting progressive neurological deterioration, surgical intervention is deemed feasible after a brief period (usually 1-7 days) of intensive preoperative antitubercular therapy. This finding suggests that short-course intensive preoperative chemotherapy may serve as a viable approach in managing such cases.
胸腰椎脊柱结核是一种严重的肺外结核,需要精确的管理策略。传统上,患者在手术前需要进行 2-4 周的四联化疗。然而,最近的临床实践已经开始探索短程(1-7 天)强化术前化疗方案的潜力。本研究旨在检查和比较这两种方法的临床效果,为最佳术前化疗持续时间提供关键见解。
在这项回顾性分析中,我们检查了 123 例接受手术治疗的胸腰椎脊柱结核患者的临床数据。根据术前化疗的持续时间,患者分为两组:短程强化化疗组(n=53,1-7 天)和传统四联化疗组(n=70,2-4 周)。我们收集并比较了两组的相关临床数据,以确定临床疗效的差异。
所有 123 例患者平均随访 2.8±0.7 年。5 例患者术后复发。患者报告明显缓解疼痛和整体良好的临床结果。在有神经功能障碍的患者中,神经症状得到改善,植入的器械被证明是有效的。所有植骨区域均观察到骨融合。
对于表现出进行性神经恶化的胸腰椎脊柱结核患者,在经过短暂(通常为 1-7 天)的强化术前抗结核治疗后,手术干预被认为是可行的。这一发现表明,短程强化术前化疗可能是治疗此类病例的一种可行方法。